Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.

Accueil
Investir
Actions
Royaume-Uni
LSE
Global Blood Therapeutics Inc (0IVZ)
Global Blood Therapeutics Inc (0IVZ) Actualités

Global Blood Therapeutics Inc (0IVZ)

0,00

0,00

(0,00%)

Fermé 23 Juin 5:30PM

Votre Hub pour des idées et discussions en direct en temps réel

Premium

MHRA Grants Marketing Authorization for GBT’s Oxbryta® (voxelotor) for Use in Great Britain for the Treatment of Hemolytic Anemia in Patients with Sickle Cell Disease Age 12 Years and Older

MHRA Grants Marketing Authorization for GBT’s Oxbryta® (voxelotor) for Use in Great Britain for the Treatment of Hemolytic Anemia in Patients...

New GBT Multinational Survey Shines a Needed Light on the Misunderstood Realities, Unseen Burden and Care Challenges of Sickle Cell Disease

New GBT Multinational Survey Shines a Needed Light on the Misunderstood Realities, Unseen Burden and Care Challenges of Sickle Cell Disease...

GBT Presents Positive New Real-World Evidence Data at EHA2022 Congress Further Supporting Clinical Use of Oxbryta® (voxelotor) in Sickle Cell Disease

GBT Presents Positive New Real-World Evidence Data at EHA2022 Congress Further Supporting Clinical Use of Oxbryta® (voxelotor) in Sickle Cell...

European Commission Approves Oxbryta® (voxelotor) for the Treatment of Hemolytic Anemia in Patients with Sickle Cell Disease Age 12 Years and Older

European Commission Approves Oxbryta® (voxelotor) for the Treatment of Hemolytic Anemia in Patients with Sickle Cell Disease Age 12 Years and...

Positive Early Access to Medicines Scheme (EAMS) Scientific Opinion Awarded to GBT’s Voxelotor for the Treatment of Haemolytic Anaemia Due to Sickle Cell Disease

Positive Early Access to Medicines Scheme (EAMS) Scientific Opinion Awarded to GBT’s Voxelotor for the Treatment of Haemolytic Anaemia Due to...

GBT’s Oxbryta® (voxelotor) Receives Positive CHMP Opinion for the Treatment of Hemolytic Anemia in Patients with Sickle Cell Disease Aged 12 Years and Older

GBT’s Oxbryta® (voxelotor) Receives Positive CHMP Opinion for the Treatment of Hemolytic Anemia in Patients with Sickle Cell Disease Aged 12...

GBT ruft Stiftung ins Leben mit dem Ziel, benachteiligten Patientengruppen weltweit eine bessere Versorgung und Unterstützung zu ermöglichen

GBT ruft Stiftung ins Leben mit dem Ziel, benachteiligten Patientengruppen weltweit eine bessere Versorgung und Unterstützung zu ermöglichen...

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Global Blood Therapeutics

Energy Transition Minerals

Jardine Matheson (PK)

Intesa Sanpaolo

BioHarvest Sciences

Northern Graphite

Ci Canadian Balanced Cor...

DJ Commodity Index Cocoa...

Bath & Body Works

Delayed Upgrade Clock

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

ADVFN

Vous avez déjà un compte? Connexion

Vous n'avez pas de compte ? Inscription

En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.